argenx
argenx's Overview
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into novel antibody-based therapies. Their first-in-class FcRn antagonist, efgartigimod (VYVGART® and VYVGART® Hytrulo), is approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) in various regions, with ongoing research into multiple other indications. argenx is focused on building a world-class, integrated immunology company, driven by science and patient needs.
Where is argenx's Headquarters?
HQ Function
Serves as the corporate and registered headquarters, overseeing global strategy, finance, investor relations, and corporate governance.
Notable Features:
Modern office facilities located in a prominent Amsterdam district, designed to support global operations and collaboration.
Work Culture:
Dynamic, innovative, and patient-centric, fostering collaboration among diverse international teams. Emphasis on scientific excellence and entrepreneurial spirit.
HQ Significance:
Strategically located in a major European business and biotech hub, facilitating access to international talent, financial markets, and collaborative opportunities.
Values Reflected in HQ: Reflects argenx's global ambition, commitment to operational excellence, and strategic positioning within the international biopharmaceutical landscape.
Location:
argenx supports global functions including research and development, clinical trials, manufacturing oversight, and commercial operations across North America, Europe, and Asia (notably Japan). The company is actively expanding its reach to bring its innovative immunology therapies to patients worldwide.
Street Address:
Willemsparkweg 153
City:
Amsterdam
State/Province:
North Holland
Country:
Netherlands
argenx's Global Presence
Ghent, Belgium
Address: Industriepark Zwijnaarde 7, 9052 Ghent, Belgium
Serves as the scientific core of the company, driving innovation in antibody engineering and immunology. It's a key site for translational medicine and early-stage development programs.
Boston, MA, USA
Address: 33 Arch Street, Boston, MA 02110, USA
Crucial for accessing the U.S. market, a key region for argenx's approved products and ongoing clinical trials. Facilitates engagement with U.S. healthcare professionals, patient advocacy groups, and regulatory authorities like the FDA.
Tokyo, Japan
Address: Kasumigaseki Building 30F, 3-2-5 Kasumigaseki, Chiyoda-ku, Tokyo 100-6030, Japan
Supports market access and commercialization of argenx's therapies in Japan, managing relationships with local regulatory bodies (PMDA) and the Japanese medical community.
Zug, Switzerland
Address: Dammstrasse 19, 6300 Zug, Switzerland
Coordinates commercial strategy, market access, and medical affairs for European countries and other international markets, supporting product launches and expansion.
Buying Intent Signals for argenx
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of argenx
As of April 2025, argenx' leadership includes:
Investors of argenx
argenx has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Over the past 12 months, argenx has significantly strengthened its executive leadership with key appointments in finance, people operations, and technical operations, reflecting its growth and strategic priorities. This includes the appointment of a new Chief Financial Officer.
Departures
New Appointments:
Technology (Tech Stack) used by argenx
Discover the tools argenx uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
argenx Email Formats and Examples
The most common email format for argenx employees is typically a combination of the first initial and last name, or first name and last name separated by a dot.
[first_initial][last]@argenx.com or [first].[last]@argenx.com
Format
jdoe@argenx.com or jane.doe@argenx.com
Example
90%
Success rate
News and media
argenx Press Release • June 21, 2024
argenx Announces U.S. FDA Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo as the first-and-only neonatal Fc receptor (FcRn) blocker for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)....more
argenx Investor Relations • May 2, 2024
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
argenx reported its financial results for the first quarter of 2024, highlighting continued revenue growth from VYVGART sales, progress in its clinical pipeline, and strategic priorities for the year. Total operating income was $413 million....more
argenx Press Release • April 16, 2024
argenx to Present New Long-Term Data from ADHERE Study of VYVGART Hytrulo in gMG at AAN Annual Meeting
argenx announced the presentation of new long-term efficacy and safety data from the ADHERE study of VYVGART Hytrulo in adults with generalized myasthenia gravis (gMG) at the American Academy of Neurology (AAN) Annual Meeting....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including argenx, are just a search away.